Typically each year, the first quarter is the slowest for biotech stocks. SunTrust Robinson Humphrey has four stocks rated Buy that should come in fine when numbers are released.
The March 31 short interest data have been compared with the previous report, and short interest decreased across the board in these selected biotech stocks.
A new Jefferies research report highlights their top growth picks for this week, and the list is dominated by top biotech stocks.
Sometimes after a stock has a good run, the analysts on Wall Street start to get a little gun-shy, especially if they made a good call on the stock and it went…
Despite a modest erosion to fundamentals and sector headwinds, Jefferies does not anticipate any dramatic earnings misses, which could help sentiment continue to turn around.
24/7 Wall St. has identified seven companies that could easily reach the $100 billion mark to become the next mega-cap stocks.
The February 29 short interest data have been compared with the previous report, and short interest decreased across the board in these selected biotech stocks.
Over the past week, Halozyme Therapeutics and a couple of other biotech companies made impressive runs.
Citigroup came out with a biotech upgrade of sorts on Thursday. The firm issued brand new Buy ratings on four of the largest names within the biotech space.
The February 12 short interest data have been compared with the previous report, and short interest increased across the board in these selected biotech stocks.
The January 29 short interest data have been compared with the previous report, and short interest was mixed in most of the selected biotech stocks.
A recent Jefferies research note indicates that the multiples for the four largest biotechs have dipped below that of the S&P for the first time since early in 2011, despite displaying higher…
Celgene reported mixed fourth-quarter financial results before the markets opened on Thursday.
Chris Lange Jefferies has four top biotech picks for 2016 that all have substantial upside and may provide investors with solid alpha for 2016.
Short interest increased in most of these selected biotech stocks for the most recent settlement date.
